---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-110343"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:28:08.326513+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Reports Q3 2025 Results and Phase 1b Data for GT-02287 in Parkinson's Disease

## Summary
- Completed enrollment of 21 participants in Phase 1b study of GT-02287, surpassing original target of 15.
- Initial data from first nine participants showed improvement in MDS-UPDRS scores, suggesting disease-slowing effect.
- Received Australian approval to extend Phase 1b dosing to 12 months; ~80% of participants joined extension.
- Net loss for Q3 2025 was $0.15 per share; cash and cash equivalents $8.8 million as of September 30, 2025.
- R&D expenses increased to $2.8 million from $2.6 million year-over-year, driven by Phase 1b trial costs.

## SEC filing metadata
- accession: 0001104659-25-110343
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/0001104659-25-110343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000110465925110343/ganx-20251112x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-110343
- JSON: https://secwatch.observer/filing/0001104659-25-110343.json
- Plain text: https://secwatch.observer/filing/0001104659-25-110343.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.